Phase I/II study of sorafenib concurrent with androgen deprivation and radiotherapy in treatment of intermediate- and high-risk localized prostate cancer.

Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer

European Urology ◽

10.1016/j.eururo.2021.03.031 ◽

2021 ◽

Author(s):

Jacob E. Berchuck ◽

Zhenwei Zhang ◽

Rebecca Silver ◽

Lucia Kwak ◽

Wanling Xie ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Damage ◽

High Risk ◽

Dna Damage Repair ◽

Androgen Deprivation ◽

Damage Repair

The Prognostic Value of Expression of HIF1α, PAK-6, and PSMB4 in Intermediate- and High-Risk Localized Prostate Cancer Patients Treated With Androgen Deprivation and Dose Escalation Radiation Therapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.06.1755 ◽

2013 ◽

Vol 87 (2) ◽

pp. S662-S663

Author(s):

A. Zapatero ◽

M. Morente ◽

C. Martin de Vidales ◽

C. Lopez ◽

M. Adrados ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Cancer Patients ◽

Dose Escalation ◽

Prognostic Value ◽

Androgen Deprivation ◽

Phase II Trial of External Radiotherapy, Brachytherapy, Androgen Deprivation and Docetaxel Chemotherapy for High-Risk, Localized Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2005.07.507 ◽

2005 ◽

Vol 63 ◽

pp. S296-S297

Author(s):

S.J. DiBiase ◽

N. Dawson ◽

Y. Kwok ◽

R. Kataria ◽

A. Hussain ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Ii ◽

Phase Ii Trial ◽

Androgen Deprivation ◽

External Radiotherapy ◽

Docetaxel Chemotherapy

Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective ? the effect of primary androgen deprivation therapy on stage C prostate cancer

BJU International ◽

10.1111/j.1464-410x.2007.06593.x ◽

2007 ◽

Vol 99 (s1) ◽

pp. 10-12 ◽

Cited By ~ 2

Author(s):

Hideyuki Akaza

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Primary Androgen Deprivation Therapy ◽

Japanese Perspective ◽

Primary Androgen Deprivation

105 oral Analysis of acute and late morbidity, and biochemical control for intermediate to high risk prostate cancer treated with androgen deprivation, HDR and 3D/IMRT: 4 year results of a phase I-II dose escalation trial

Radiotherapy and Oncology ◽

10.1016/s0167-8140(04)80156-7 ◽

2004 ◽

Vol 71 ◽

pp. S52-S53

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase I ◽

Dose Escalation ◽

Androgen Deprivation ◽

Biochemical Control ◽

High Risk Prostate Cancer ◽

Late Morbidity ◽

Risk Prostate Cancer

Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2018.10.005 ◽

2019 ◽

Vol 103 (2) ◽

pp. 344-352 ◽

Cited By ~ 2

Author(s):

Joan Carles ◽

Enrique Gallardo ◽

Montserrat Doménech ◽

Albert Font ◽

Joaquim Bellmunt ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Cancer Patients ◽

Randomized Study ◽

Androgen Deprivation ◽

Phase 2 ◽

Weekly Docetaxel

Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer

The Journal of Steroid Biochemistry and Molecular Biology ◽

10.1016/j.jsbmb.2011.12.019 ◽

2012 ◽

Vol 129 (3-5) ◽

pp. 179-190 ◽

Cited By ~ 9

Author(s):

Tsutomu Nishiyama

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.11.418 ◽

2020 ◽

Vol 106 (5) ◽

pp. 939-947

Author(s):

Jianqing Lin ◽

Robert B. Den ◽

Jacob Greenspan ◽

Timothy N. Showalter ◽

Jean H. Hoffman-Censits ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase I ◽

Phase I Trial ◽

Androgen Deprivation ◽

Intensity Modulated ◽

High Risk Prostate Cancer ◽

Risk Prostate Cancer

Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-1021-03 ◽

2004 ◽

Vol 10 (4) ◽

pp. 1306-1311 ◽

Cited By ~ 33

Author(s):

Tomasz M. Beer ◽

Mark Garzotto ◽

Bruce A. Lowe ◽

William J. Ellis ◽

Michelle A. Montalto ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase I ◽

Phase I Study ◽

The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy

Radiation Oncology ◽

10.1186/1748-717x-7-66 ◽

2012 ◽

Vol 7 (1) ◽

Cited By ~ 26

Author(s):

Damien C Weber ◽

Jean-Christophe Tille ◽

Christophe Combescure ◽

Jean-François Egger ◽

Mahomet Laouiti ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Prognostic Value ◽

Androgen Deprivation ◽

High Risk Patients ◽

Risk Patients